{
    "Trade/Device Name(s)": [
        "Immunalysis SEFRIA Fentanyl Urine Enzyme Immunoassay",
        "Immunalysis Fentanyl Urine Calibrators"
    ],
    "Submitter Information": "Immunalysis Corporation",
    "510(k) Number": "K161216",
    "Predicate Device Reference 510(k) Number(s)": [
        "K150606"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "DLJ",
        "DJG"
    ],
    "Summary Letter Date": "May 30, 2017",
    "Summary Letter Received Date": "June 1, 2017",
    "Submission Date": "June 13, 2017",
    "Regulation Number(s)": [
        "21 CFR 862.3650"
    ],
    "Regulation Name(s)": [
        "Opiate test system"
    ],
    "Analyte Class(es)": [
        "toxicology"
    ],
    "Analyte(s)": [
        "Fentanyl"
    ],
    "Specimen Type(s)": [
        "Urine"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [
        "Automated clinical chemistry analyzers",
        "Beckman Coulter AU 400e"
    ],
    "Method(s)/Technology(ies)": [
        "Enzyme immunoassay"
    ],
    "Methodologies": [
        "Immunoassay"
    ],
    "Submission Type(s)": [
        "Assay",
        "Calibrator"
    ],
    "Document Summary": "FDA 510(k) summary for Immunalysis SEFRIA Fentanyl Urine Enzyme Immunoassay and Fentanyl Urine Calibrators for qualitative detection of fentanyl in urine using automated clinical chemistry analyzers.",
    "Indications for Use Summary": "Qualitative laboratory test for the detection of fentanyl in human urine with automated clinical chemistry analyzers; provides preliminary results for prescription use, with mass spectrometry recommended for confirmation.",
    "fda_folder": "Toxicology"
}